Highlights Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Real-time Estimate Cboe BZX Other stock markets 14:51:16 14/05/2024 BST			5-day change	1st Jan Change
2.63 ^USD	+0.38%		-23.69%	+15.95%

05-09	Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
05-09	Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	05-09	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q4 Revenue $10.7M, vs. Street Est of $14.8M	02-28	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Mersana Therapeutics, Inc. Announces Business Updates	01-05	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Mersana Therapeutics, Inc. Announces FDA Has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056	31/10/23	CI
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q2 Revenue $10.7M	08/08/23	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Mersana Therapeutics, Inc. Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization	27/07/23	CI
Mersana Therapeutics Says FDA Issues Partial Clinical Hold on Enrollment in Ovarian Cancer Drug Trials; Shares Plunge	15/06/23	MT
Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials	15/06/23	CI
Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $7.8M, vs. Street Est of $18.3M	09/05/23	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Mersana Therapeutics, Inc. Announces Phase 1 Trial of XMT-2056 Has Been Placed on Clinical Hold by the U.S. Food and Drug Administration	13/03/23	CI
Mersana Therapeutics Q4 Loss Narrows, Revenue Climbs	28/02/23	MT
Mersana Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Mersana Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	28/02/23	CI
Mersana Therapeutics, Inc. Initiates Expansion Portion of Upgrade-A Combination Clinical Trial in Platinum-Sensitive Ovarian Cancer	01/02/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Highlights

Filters